BVF
San Francisco, CAfiles as BVF INC/IL
$3.9bn in 44 US stocks at the end of 30 June 2026. The top 10 are 65.6% of the money. It changed about 17.9% of the portfolio this quarter.
Value
$3.9bn
Stocks
44
Top 10 share
65.6%
Turnover
17.9%
What changed this quarter
New
Bought for the first time this quarter.
- Q32 BioQTTB0.8% of the fund
- AbsciABSI0.7% of the fund
- Sagimet BiosciencesSGMT0.5% of the fund
- ImmunicIMUX0.3% of the fund
- Research Alliance Corp IIIRACC0.1% of the fund
- Entera BioENTX0.1% of the fund
- Engene TherapeuticsENGNW<0.1% of the fund
Added
Bought more of a stock they already held.
- Revolution MedicinesRVMD14.2% of the fund+4%
- Xoma Royalty8.3% of the fund+193%
- Alkermes plc.ALKS2.9% of the fund+8%
- Avalo TherapeuticsAVTX1.0% of the fund+27%
- InvivydIVVD0.6% of the fund+44%
- OnKure TherapeuticsOKUR0.4% of the fund+64%
Cut
Sold some of their stake.
- Kymera TherapeuticsKYMR11.4% of the fund-30%
- Structure TherapeuticsGPCR4.6% of the fund-3%
- Nektar TherapeuticsNKTR4.3% of the fund-7%
- Mirum PharmaceuticalsMIRM3.2% of the fund-33%
- Palvella TherapeuticsPVLA2.6% of the fund-30%
- ZymeworksZYME2.4% of the fund-2%
- Disc MedicineIRON2.2% of the fund-9%
- Tyra BiosciencesTYRA1.2% of the fund-25%
Sold out
Sold their entire stake.
- Compass TherapeuticsCMPX-100%
- SepternaSEPN-100%
- ImmunicIMUX-100%
- Engene HoldingsENGNW-100%
Holdings
- Xoma Royalty
- Share
- 8.3%
- Value
- $323m
- Shares
- 7,593,303
+193%
- Structure TherapeuticsGPCR
- Share
- 4.6%
- Value
- $181m
- Shares
- 3,366,823
-3%
- Immunocore HldgsIMCR
- Share
- 1.1%
- Value
- $41m
- Shares
- 1,294,463
Held
- Research Alliance Corp IIIRACC
- Share
- 0.1%
- Value
- $5m
- Shares
- 500,000
New
- Molecular Partners AGMOLN
- Share
- 0.1%
- Value
- $5m
- Shares
- 1,353,968
Held
- Engene TherapeuticsENGNW
- Share
- <0.1%
- Value
- $274,072
- Shares
- 945,402
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Revolution MedicinesRVMD | 14.2% | $555m | 2,965,160 | +4% |
| Kymera TherapeuticsKYMR | 11.4% | $444m | 3,872,052 | -30% |
| Xoma Royalty | 8.3% | $323m | 7,593,303 | +193% |
| MoonLake ImmunotherapeuticsMLTX | 8.0% | $312m | 16,001,284 | Held |
| GH ResearchGHRS | 5.9% | $233m | 8,650,158 | Held |
| Structure TherapeuticsGPCR | 4.6% | $181m | 3,366,823 | -3% |
| Nektar TherapeuticsNKTR | 4.3% | $167m | 2,391,075 | -7% |
| Mirum PharmaceuticalsMIRM | 3.2% | $124m | 1,056,027 | -33% |
| XencorXNCR | 2.9% | $115m | 7,133,720 | Held |
| Alkermes plc.ALKS | 2.9% | $113m | 2,154,704 | +8% |
| Monte Rosa TherapeuticsGLUE | 2.8% | $108m | 4,460,886 | Held |
| Cullinan TherapeuticsCGEM | 2.7% | $105m | 5,750,683 | Held |
| Palvella TherapeuticsPVLA | 2.6% | $103m | 672,789 | -30% |
| ZymeworksZYME | 2.4% | $95m | 3,649,142 | -2% |
| Kura OncologyKURA | 2.4% | $93m | 8,445,769 | Held |
| Disc MedicineIRON | 2.2% | $84m | 1,153,612 | -9% |
| Stoke TherapeuticsSTOK | 2.1% | $83m | 2,547,557 | Held |
| Olema PharmaceuticalsOLMA | 1.7% | $66m | 5,295,893 | Held |
| AnnexonANNX | 1.3% | $50m | 8,698,173 | Held |
| Crescent BiopharmaCBIO | 1.3% | $49m | 2,748,763 | Held |
| AC Immune SAACIU | 1.2% | $47m | 19,822,436 | Held |
| Tyra BiosciencesTYRA | 1.2% | $47m | 1,476,196 | -25% |
| Sutro BiopharmaSTRO | 1.1% | $42m | 1,251,788 | Held |
| Immunocore HldgsIMCR | 1.1% | $41m | 1,294,463 | Held |
| Avalo TherapeuticsAVTX | 1.0% | $38m | 2,075,545 | +27% |
| 4D Molecular TherapeuticsFDMT | 1.0% | $38m | 2,879,289 | Held |
| Q32 BioQTTB | 0.8% | $30m | 2,350,000 | New |
| Anteris Technologies GlobalAVR | 0.8% | $30m | 3,000,000 | Held |
| Foghorn TherapeuticsFHTX | 0.7% | $29m | 5,842,000 | Held |
| AbsciABSI | 0.7% | $27m | 2,361,674 | New |
| Eledon PharmaceuticalsELDN | 0.6% | $25m | 6,293,282 | Held |
| InvivydIVVD | 0.6% | $25m | 28,165,000 | +44% |
| Sagimet BiosciencesSGMT | 0.5% | $19m | 2,500,000 | New |
| OnKure TherapeuticsOKUR | 0.4% | $15m | 3,235,778 | +64% |
| ImmunicIMUX | 0.3% | $12m | 765,295 | New |
| X4 PharmaceuticalsXFOR | 0.3% | $10m | 2,233,742 | Held |
| ImageneBioIMA | 0.2% | $7m | 1,110,002 | Held |
| TScan TherapeuticsTCRX | 0.1% | $5m | 5,564,290 | Held |
| Research Alliance Corp IIIRACC | 0.1% | $5m | 500,000 | New |
| Molecular Partners AGMOLN | 0.1% | $5m | 1,353,968 | Held |
| Tenax TherapeuticsTENX | 0.1% | $5m | 339,549 | Held |
| Entera BioENTX | 0.1% | $4m | 2,425,000 | New |
| InventivaIVA | <0.1% | $3m | 686,040 | Held |
| Engene TherapeuticsENGNW | <0.1% | $274,072 | 945,402 | New |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 39.7% since 30 June 2025.
Where the money is
Health care85.9%
Other14.1%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.